ProShare Advisors
BBIO icon

ProShare Advisors’s BridgeBio Pharma BBIO Stock Holding History

ProShare Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$478K Sell
6,421
-25,256
-80% -$1.77M ﹤0.01% 1121
2026
Q1 		$2.35M Sell
31,677
-5,843
-16% -$424K ﹤0.01% 675
2025
Q4 		$2.87M Buy
37,520
+3,970
+12% +$261K 0.01% 659
2025
Q3 		$1.74M Sell
33,550
-5,606
-14% -$273K ﹤0.01% 712
2025
Q2 		$1.69M Buy
39,156
+136
+0.3% +$4.95K ﹤0.01% 705
2025
Q1 		$1.35M Sell
39,020
-9,519
-20% -$321K ﹤0.01% 742
2024
Q4 		$1.33M Buy
48,539
+10,864
+29% +$281K ﹤0.01% 811
2024
Q3 		$959K Buy
37,675
+10,498
+39% +$276K ﹤0.01% 826
2024
Q2 		$688K Sell
27,177
-6,104
-18% -$167K ﹤0.01% 840
2024
Q1 		$1.03M Buy
33,281
+3,209
+11% +$109K ﹤0.01% 780
2023
Q4 		$1.21M Buy
30,072
+4,569
+18% +$137K ﹤0.01% 724
2023
Q3 		$673K Buy
25,503
+223
+0.9% +$6.33K ﹤0.01% 805
2023
Q2 		$435K Buy
25,280
+2,324
+10% +$35K ﹤0.01% 1033
2023
Q1 		$381K Sell
22,956
-3,030
-12% -$35.3K ﹤0.01% 1065
2022
Q4 		$198K Buy
25,986
+1,985
+8% +$19K ﹤0.01% 1506
2022
Q3 		$239K Sell
24,001
-1,019
-4% -$10.6K ﹤0.01% 1287
2022
Q2 		$227K Sell
25,020
-12,617
-34% -$106K ﹤0.01% 1394
2022
Q1 		$381K Sell
37,637
-8,968
-19% -$92K ﹤0.01% 1467
2021
Q4 		$778K Sell
46,605
-1,766
-4% -$74.7K ﹤0.01% 1183
2021
Q3 		$2.27M Sell
48,371
-6,373
-12% -$342K 0.01% 691
2021
Q2 		$3.34M Buy
54,744
+8,822
+19% +$504K 0.01% 592
2021
Q1 		$2.83M Buy
45,922
+10,872
+31% +$711K 0.01% 591
2020
Q4 		$2.49M Buy
35,050
+6,404
+22% +$309K 0.01% 581
2020
Q3 		$1.07M Sell
28,646
-646
-2% -$20.3K 0.01% 705
2020
Q2 		$955K Buy
29,292
+7,894
+37% +$240K 0.01% 726
2020
Q1 		$621K Sell
21,398
-8,388
-28% -$260K ﹤0.01% 692
2019
Q4 		$1.04M Buy
+29,786
New +$826K ﹤0.01% 787

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

ProShare Advisors's BBIO Position: Q2 2026 in Review

ProShare Advisors reduced its BridgeBio Pharma (BBIO) stake by 80% in Q2 2026, selling an estimated $1.77M and leaving 6,421 shares worth $478K. The position accounts for ﹤0.01% of the portfolio, ranked #1121.

ProShare Advisors first reported a position in BBIO in Q4 2019 and has held it in 27 quarters since. The position peaked at $3.34M in Q2 2021. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • ProShare Advisors held 6,421 shares of BridgeBio Pharma worth $478K as of Q2 2026.
  • ProShare Advisors sold 25,256 BridgeBio Pharma shares in Q2 2026, an estimated $1.77M.
  • BridgeBio Pharma made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1121 holding.
  • ProShare Advisors first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 27 quarters since.
  • ProShare Advisors's BridgeBio Pharma position peaked at $3.34M in Q2 2021.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.